NL-OMON29096已完成不适用
A randomized phase III study on the effect of the chimeric anti-CD20 monoclonal antibody (MabThera) during sequential chemotherapy followed by autologous stem cell transplantation in patients with relapsed or progressive B-cell non-Hodgkin’s lymphoma.
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl0 个研究点目标入组 300 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Malignant lymphoma based upon a representative histology specimen according to the REAL classification at relapse or progression: Follicular center lymphoma, follicular (grade III), Diffuse large B-cell lymphoma, Primary mediastinal B-cell lymphoma;
- •2. CD20 positive;
排除标准
- •1. Patients with history of intolerance of exogenous protein administration;
- •2. Patients with severe cardiac dysfunction (NYHA classification II-IV);
研究者
相似试验
招募中
不适用
OROCSON study: Late Onset Recurrent Ovarian Cancer: Surgery Or Not.NL-OMON27781700
招募中
3 期
A randomized phase III study to evaluate the effectiveness of two different dosing regimens (high dose vs daily) of Prednisone for boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects.Musculoskeletal - Other muscular and skeletal disordersDuchenne muscular dystrophyACTRN12605000075684The Children's Hospital at Westmead140
已完成
3 期
A randomized phase III study to evaluate the effects of Oxpentifyllene as an add on therapy for boys with duchenne muscular dystrophy in improving muscle strength and function.Musculoskeletal - Other muscular and skeletal disordersDuchenne muscular dystrophyACTRN12605000078651The Children's Hospital at Westmead64
进行中（未招募）
1 期
Progressive Exercise for Anabolism in Kidney DiseaseACTRN12605000101684Kidney Health Australia50
尚未招募
不适用
A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab.Chronic Lymphocytic LeukemiaNL-OMON25345Dr. C.H. GeislerRigshospitaletDept. of Hematology (L 4042)Blegdamsvej 9DK-2100 CopenhagenDenmarkTel: 0045 35451146Fax: 0045 35454283e-mail:geisler@rh.dk300